"Coxsackievirus: Australia-based Viralytics has been developing an engineered form of coxsackievirus, a cause of the common cold. The compound, called Cavatak, is being tested in several different combinations, including one with Keytruda and a second with another BMS checkpoint inhibitor, Yervoy (ipilimumab), both in melanoma. Early results are impressive: Seven out of 10 patients in the Keytruda trial saw their tumors shrink, while 14 of 18 patients in the Yervoy trial saw their disease come under control, the company announced in October."
..
VLA Price at posting:
$1.21 Sentiment: Buy Disclosure: Held
